In trading on Tuesday, shares of the ProShares Ultra High Yield ETF (Symbol: UJB) crossed below their 200 day moving average of $78.36, changing hands as low as $78.05 per share. ProShares Ultra High Yield shares are currently trading off about 0.6% on the day. The chart below
In trading on Tuesday, shares of the ProShares Ultra High Yield ETF (Symbol: UJB) crossed below their 200 day moving average of $78.36, changing hands as low as $78.05 per share. ProShares Ultra High Yield shares are currently trading off about 0.6% on the day. The chart below
As demand from artificial intelligence data centers drives copper to new records, Citi believes that there's still more room for the metal to run. Copper's July-dated futures notched a back-to-back record close on Tuesday, settling up 1.09% to 6.531. Year to date, copper prices have risen 14.9%, while they've added 7.8% alone since the start of the Iran war. Copper traded on the London Metal Excha...
As demand from artificial intelligence data centers drives copper to new records, Citi believes that there's still more room for the metal to run. Copper's July-dated futures notched a back-to-back record close on Tuesday, settling up 1.09% to 6.531. Year to date, copper prices have risen 14.9%, while they've added 7.8% alone since the start of the Iran war. Copper traded on the London Metal Exchange added 0.56% to $14,021 per metric ton on Tuesday, also closing at another record. In a Monday note to clients, Citi strategist Charlie Massy-Collier attributed this move higher to demand stemming from artificial intelligence data centers. "Practically all copper demand growth since 2022 has come from energy transition and AI related sources," the strategist wrote. "Another, more recent, channel for demand growth arises from strategic inventory stockpiling, where Citi specialists have mapped out potential price implications of strategic inventory build scenarios." Despite this recent runup, Massy-Collier believes that the metal's recent move above the $13,500 threshold is confirmation that an improving macroeconomic backdrop can help drive prices even higher. The strategist's bull-case forecast is $15,000 per metric ton, or approximately 7% above the metal's Tuesday close. "We had been apprehensive about buying copper in recent weeks given the strength of resistance seen at $13,500. We are of the view that this resistance was at least in part a function of strong global visible inventory builds in Q1, indicating physical pushback at these prices despite the positive macro backdrop at the time," Massy-Collier said. The strategist added: "As such, our interpretation of the recent break above $13,500 is one of the market confirming the strength of both the structural and cyclical demand setup, giving us conviction to chase the move higher." Massy-Collier is implementing this trade through the purchase of an LME copper digital call option at 15,250, which expires on Aug. 5.
In trading on Tuesday, shares of Yum! Brands Inc (Symbol: YUM) crossed above their 200 day moving average of $152.33, changing hands as high as $154.24 per share. Yum! Brands Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performa
In trading on Tuesday, shares of Yum! Brands Inc (Symbol: YUM) crossed above their 200 day moving average of $152.33, changing hands as high as $154.24 per share. Yum! Brands Inc shares are currently trading up about 2.1% on the day. The chart below shows the one year performa
OpenAI unveiled Daybreak Monday night, positioning its new cybersecurity product as an answer to Anthropic's Mythos as other cybersecurity stocks hold steady.
OpenAI unveiled Daybreak Monday night, positioning its new cybersecurity product as an answer to Anthropic's Mythos as other cybersecurity stocks hold steady.
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026.
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the first quarter ended March 31, 2026.
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression
Utilization Gains Underpin Improving Same-Location Revenue Fifth Asset Sale Under Asset Rotation Strategy Reduced Leverage with $12.6 Million of Paydowns Conference Call Will be Held on May 12, 2026, at 4:30 PM Eastern Time
Utilization Gains Underpin Improving Same-Location Revenue Fifth Asset Sale Under Asset Rotation Strategy Reduced Leverage with $12.6 Million of Paydowns Conference Call Will be Held on May 12, 2026, at 4:30 PM Eastern Time
IRVING, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, announced today that it will host a live conference call with the financial community on May 14, 2026 at 5:00 pm Eastern Time to discus...
IRVING, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- XBP Global Holdings, Inc. (“XBP Global” or “the Company”) (NASDAQ: XBP), a multinational technology and services company orchestrating mission-critical systems that enable hyper-automation and digital transformation, announced today that it will host a live conference call with the financial community on May 14, 2026 at 5:00 pm Eastern Time to discuss its first quarter 2026 financial results, accompanied by a live webcast. The press release announcing first quarter 2026 results will be issued after market close on May 14, 2026.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update.
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026
Next anticipated Revita ® clinical data readouts are 1-year data from the REVEAL-1 Cohort in Q2 2026 and 1-year randomized data from the REMAIN-1 Midpoint Cohort in Q3 2026
SARATOGA SPRINGS, N.Y., May 12, 2026 (GLOBE NEWSWIRE) -- Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first nine months of fiscal year 2026.
SARATOGA SPRINGS, N.Y., May 12, 2026 (GLOBE NEWSWIRE) -- Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first nine months of fiscal year 2026.
ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fi...
ZUG, Switzerland, May 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the first quarter ended in March 31, 2026, and provided a business update.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced that it will participate in the following upcoming financial conferences during the second quarter of 2026: J.P. Morgan 2026 Global Technology, Media and Communications Conference on May 19th in Boston. Astera ...
SAN JOSE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Astera Labs, Inc. (Nasdaq: ALAB), a leader in semiconductor-based connectivity solutions for rack-scale AI infrastructure, today announced that it will participate in the following upcoming financial conferences during the second quarter of 2026: J.P. Morgan 2026 Global Technology, Media and Communications Conference on May 19th in Boston. Astera Labs’ presentation is scheduled for 10:05 am ET.TD Cowen's 54th Annual Technology, Media & Telecom C
Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Dr. Tomislav Mihaljevic to Oracle's Board of Directors and increased the size of the Board to 13. The election is effective as of May 6, 2026.
Oracle Corporation (NYSE: ORCL) today announced that it unanimously elected Dr. Tomislav Mihaljevic to Oracle's Board of Directors and increased the size of the Board to 13. The election is effective as of May 6, 2026.
franckreporter Wall Street finished mostly lower on Tuesday after a hotter-than-expected inflation report and renewed concerns surrounding the fragile U.S.-Iran ceasefire pressured investor sentiment across major asset classes. The technology-heavy Nasdaq Composite ( COMP:IND ) led declines, falling -0.7%, while the benchmark S&P 500 ( SP500 ) slipped -0.1%. The blue-chip Dow Jones Industrial Aver...
franckreporter Wall Street finished mostly lower on Tuesday after a hotter-than-expected inflation report and renewed concerns surrounding the fragile U.S.-Iran ceasefire pressured investor sentiment across major asset classes. The technology-heavy Nasdaq Composite ( COMP:IND ) led declines, falling -0.7%, while the benchmark S&P 500 ( SP500 ) slipped -0.1%. The blue-chip Dow Jones Industrial Average ( DJI ) managed a modest +0.1% gain. Seeking Alpha analyst Andrew Hecht said inflationary pressures continue to intensify as higher energy costs linked to Middle East hostilities ripple through the broader economy. “CPI was up 0.6% for April, or 3.8% annually, the highest inflation reading since May 2023,” Hecht noted, adding that the core inflation reading remained “well above the Fed’s stated 2% target.” Hecht also pointed to weakening wage trends, saying real average hourly earnings declined both monthly and annually, creating additional pressure for consumers. According to Hecht, markets are increasingly pricing in elevated interest rates for longer, while unresolved tensions between the U.S. and Iran could further boost crude oil prices, “the critical factor for markets across all asset classes.” Market Tracking ETFs: ( DIA ), ( DDM ), ( DOG ), ( DXD ), ( SDOW ), ( SPY ), ( VOO ), ( IVV ), ( RSP ), ( SSO ), ( UPRO ), ( SH ), ( SDS ), ( SPXU ), ( QQQ ), ( QQQM ), ( TQQQ ), ( QID ), and ( SQQQ ). More on markets Trump says trade talks will take center stage in high-stakes summit with Xi SpaceX may become the largest company on the planet, says Ron Baron China’s high-tech exports surge nearly 40% as AI demand accelerates Michael Burry issues new market warning as stocks push to record highs Goldman Sachs flags Amazon and Alphabet for inflating S&P 500 earnings growth figures
Oklo press release ( OKLO ): Q1 net loss was $33.1 million. Loss from operations of $51.2 million, made up of payroll, stock-based compensation, general business expenses, and professional fees Cash and marketable securities of $2.5 billion comprised of cash and equivalents of $1.6 billion and marketable securities of $0.9 billion. More on Oklo Oklo: Q1 Earnings Is The Inflection Point For The SMR...
Oklo press release ( OKLO ): Q1 net loss was $33.1 million. Loss from operations of $51.2 million, made up of payroll, stock-based compensation, general business expenses, and professional fees Cash and marketable securities of $2.5 billion comprised of cash and equivalents of $1.6 billion and marketable securities of $0.9 billion. More on Oklo Oklo: Q1 Earnings Is The Inflection Point For The SMR Trade Oklo: Why Near-Term Isotope Catalysts Make This Fast Reactor Stock A Speculative Buy Oklo: Positioned To Power The AI Infrastructure Boom OKLO, OTTR draw highest short interest in utilities sector; BIP and MGEE see lowest short interest Oklo rated a new Buy, NuScale a Hold at HSBC
Lineage Cell Therapeutics press release ( LCTX ): Q1 GAAP EPS of -$0.03 misses by $0.01 . Revenue of $1.72M (+14.7% Y/Y) misses by $1.36M . Operating Expenses: Operating expenses are composed of research and development (“R&D”) expenses and general and administrative (“G&A”) expenses. Total operating expenses for the three months ended March 31, 2026 were $9.3 million, an increase of $1.3 million ...
Lineage Cell Therapeutics press release ( LCTX ): Q1 GAAP EPS of -$0.03 misses by $0.01 . Revenue of $1.72M (+14.7% Y/Y) misses by $1.36M . Operating Expenses: Operating expenses are composed of research and development (“R&D”) expenses and general and administrative (“G&A”) expenses. Total operating expenses for the three months ended March 31, 2026 were $9.3 million, an increase of $1.3 million as compared to $8.0 million for the same period in 2025. R&D Expenses: R&D expenses for the three months ended March 31, 2026 were $4.2 million, an increase of $1.1 million as compared to $3.1 million for the same period in 2025. The net increase was primarily driven by $0.3 million for our OPC1 program, $0.2 million for our ReSonance program, and approximately $0.7 million for our preclinical and other undisclosed programs. G&A Expenses: G&A expenses for the three months ended March 31, 2026 were approximately $5.1 million, an increase of $0.2 million as compared to $4.9 million for the same period in 2025. The net increase was primarily driven by personnel costs, partially offset by services provided by third parties. Loss from Operations: Loss from operations for the three months ended March 31, 2026 was $7.6 million, an increase of $1.1 million as compared to $6.5 million for the same period in 2025. Other Income/(Expenses): Other income/(expenses) for the three months ended March 31, 2026 reflected other income of $2.8 million, compared to other income of approximately $2.4 million for the same period in 2025. The net increase was primarily driven by exchange rate fluctuations related to Lineage’s international subsidiaries and no warrant-related financing transaction costs incurred as compared to the prior year’s quarter. More on Lineage Cell Therapeutics Lineage Cell Therapeutics, Inc. (LCTX) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript Lineage Cell Therapeutics Q1 2026 Earn...
Yoni Assia, eToro CEO join Bloomberg Businessweek Daily on their reccent earnings beat. EToro Group reported adjusted earnings per share for the first quarter that beat the average analyst estimate. He also discusses retail trade sentiment, crypto and how AI is changing the trading landscape. (Source: Bloomberg)
Yoni Assia, eToro CEO join Bloomberg Businessweek Daily on their reccent earnings beat. EToro Group reported adjusted earnings per share for the first quarter that beat the average analyst estimate. He also discusses retail trade sentiment, crypto and how AI is changing the trading landscape. (Source: Bloomberg)